Articles tagged with Parkinsons Disease
Research found that Parkinson's disease patients developing impulse control disorders show increased rates of depression, appetite changes, and irritability compared to those without the disorder. The study identified nine patients with impulse control disorders, including pathological gambling, hypersexuality, and excessive shopping.
A large collaborative effort has made publicly available genetic data for Parkinson's research, providing new opportunities for future studies. The data includes genotypes from hundred of patients and healthy controls, which may help identify common genetic variability that results in minor and moderate risk for disease.
A team of researchers used a sophisticated laser system to gain evidence that neuromelanin, a dark brown pigment accumulating in brains, consists of layers of two other pigments: eumelanin and pheomelanin. This structural arrangement may play a critical role in the neurodegenerative cascade behind Parkinson's disease.
Researchers found accelerated brain changes in people with Parkinson's, while mice exposed to pesticides showed increased oxidative stress and reduced dopamine uptake. Exposure to banned pesticides like dieldrin may increase the risk of developing Parkinson's earlier in life.
UT Southwestern researchers found that blocking tumor necrosis factor, an inflammatory molecule, reduces dopamine neuron death in rats with Parkinson's disease. The study suggests that TNF-dependent inflammation may contribute to the progression of the disease.
Researchers investigated the impact of two copies of the G2019S Parkinson's gene mutation on disease severity. They found no observable differences in symptoms, age of onset, or life expectancy between those with two copies and those with only one copy.
Researchers discovered that dopamine neurons in manganese-exposed animals don't release dopamine when stimulated, suggesting a dysfunctional dopamine system. The study found effects of manganese exposure at high blood concentrations, similar to those in children and adults with environmental or occupational exposure.
The University of Pittsburgh has been designated as an American Parkinson Disease Association Advanced Center for Parkinson's Disease Research. The center will focus on developing early diagnosis methods and understanding iron accumulation in the PD brain. Dr. J. Timothy Greenamyre will direct the center.
A large international study provides strong evidence that common genetic variants in the alpha-synuclein gene contribute to Parkinson's disease worldwide. Variability in this gene is associated with a 1.5 times greater risk for the disease, highlighting potential therapies to reduce alpha-synuclein protein production.
Research found that SNCA gene variability is associated with an increased risk of Parkinson disease, explaining approximately 3% of the population's susceptibility. The study also suggests that this variation may be a common factor in the development of the disease.
A five-year study by The Parkinson's Institute suggests that nicotine treatment can reduce dopamine cell damage in Parkinson's disease. This protective effect may explain the lower incidence of Parkinson's among smokers, and could potentially lead to new therapy options for early-stage patients.
Researchers at Mayo Clinic have discovered an association between allergic rhinitis and the development of Parkinson's disease. The study found that people with allergic rhinitis are 2.9 times more likely to develop Parkinson's, highlighting a potential link between inflammation and the disease.
Researchers at the Montreal Neurological Institute have made a groundbreaking discovery about the parkin gene, which plays a novel role in nerve cell survival. This finding may help identify potential treatment targets for Parkinson's disease and other neurodegenerative disorders.
Researchers have created a new genetic model for Parkinson's disease using mice with a deleted TFAM gene, which mimics the human condition. The study shows that dopamine-producing nerve cells in the brain stem degenerate slowly, similar to humans with Parkinson's disease.
A study found that alterations in the glucocerebrosidase (GBA) gene contribute to dementia with Lewy bodies (DLB), a common neurodegenerative disease. Researchers sequenced DNA from autopsy samples and identified mutations in the GBA gene in nearly 40% of DLB patients.
Researchers found that direct neurologist involvement improves Parkinson's disease symptoms for patients undergoing deep brain stimulation, leading to reduced tremors and medication dosages. This study emphasizes the importance of personalized care by experts in movement disorders and deep brain stimulation.
A recent study found that apathy is a core feature of Parkinson's disease and may occur in up to 51% of patients. Apathy with no depression was also present in 29% of those with Parkinson's disease, highlighting the need for accurate diagnosis and treatment.
A study by Emory University researchers found a connection between developmental exposure to the pesticide dieldrin and an increased risk of developing Parkinson's disease. The study suggests that early life exposures may contribute to neurodegeneration later in life.
A study of 143,325 participants found a strong association between pesticide exposure and Parkinson's disease, with a 70% higher incidence among those exposed. The association was strongest among individuals who used pesticides at home or in gardening, regardless of occupation or sex.
A large cohort study found that chronic pesticide exposure is associated with an increased risk of Parkinson's disease, regardless of occupation or home use. The study suggested that exposure to specific pesticides may be the underlying cause of this increased risk.
Researchers at Whitehead Institute identified a critical biological pathway responsible for Parkinson's symptoms and developed a treatment to repair it. Increasing levels of a transport protein restored normal neurological function in animal models, including fruit flies, worms, and rats with alpha-synuclein-induced Parkinson's symptoms.
Researchers have identified a key defect in ER-to-Golgi trafficking that contributes to alpha-synuclein toxicity, a hallmark of Parkinson's disease. Enhancing this pathway may suppress alpha-synuclein toxicity and protect dopamine-producing neurons.
Researchers identified minocycline's role in blocking poly(ADP-ribose) polymerase-1 (PARP-1), a protein linked to inflammation and cell death. The study suggests minocycline's potential as a treatment for neurodegenerative diseases, but raises concerns about its effects on cancer risk and gender differences.
A study found that REM sleep behavior disorder is a precursor to neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies. Patients with RBD are at increased risk for developing these conditions, which can lead to serious consequences like brain hemorrhages and death.
A new study by Mayo Clinic researchers found that pesticide use increases the risk of Parkinson's disease in men, with a higher likelihood of exposure compared to women. The study matched individuals with Parkinson's disease to those without, assessing exposure via farming occupation or hobbies.
Researchers found that individuals with one mutated parkin gene and one normal gene (heterozygotes) developed Parkinson's disease 11.7 years earlier than those with no mutations, indicating a stronger genetic effect than previously recognized.
Researchers found that individuals with a single copy of the parkin gene mutation exhibit an average age of onset around 43 years old. This discovery challenges current understanding and highlights the need for further investigation into the role of partial parkin gene expression in Parkinson's disease.
Researchers discovered that an aspirin-like drug called sodium para-aminosalicylic acid dramatically reduces symptoms of manganese intoxication. The treatment has been shown to reverse Parkinson-type symptoms even 17 years after initial exposure.
A study identifies Protein Disulphide Isomerase as a marker for neurodegenerative diseases, while also showing its potential as a therapeutic target. The research reveals that NO attacks PDI via S-nitrosylation, altering its function and leading to nerve cell injury.
Researchers found a connection between DJ-1 protein and neurodegeneration in Parkinson's disease, suggesting that environmental toxins may trigger oxidative stress. The study suggests that understanding the role of DJ-1 may lead to the development of new treatments for Parkinson's disease and potentially other neurological disorders.
UB researchers have discovered an agent, L-AP4, that activates group III metabotropic glutamate receptors and reverses damage caused by rotenone. The findings could lead to a new treatment for Parkinson's disease.
Research identifies three estrogen-related gene variants associated with an increased risk of Parkinson's disease in women. The study found that these genetic variations affect 10-20% of the female population and could be used to predict disease risk using a simple blood test.
The new guidelines provide recommendations for early diagnosis, effective therapies, and screening for depression and psychosis. Regular exercise and therapy can also help manage movement difficulties, improving overall quality of life for those with Parkinson disease.
Researchers at MIT have discovered a compound called B2 that promotes the formation of large protein inclusions, which may help stop Huntington's disease progression. The compound also shows promise for treating Parkinson's disease, another neurodegenerative disorder caused by misfolded proteins.
A male-specific gene, SRY, has been found to be linked to the control of physical movement and may contribute to the higher incidence of Parkinson's disease in men. The protein, which determines male gender, was discovered in British scientists in 1990.
Researchers found that male-specific gene SRY is required for normal brain function of dopamine-secreting neurons. This may help explain the higher incidence of Parkinson's disease in males, which exhibits a 3:2 ratio with females.
Researchers found that the SRY gene plays a crucial role in regulating dopamine-producing brain cells, which malfunction in Parkinson's disease. The study suggests that men are more susceptible to the disease due to lower levels of this gene, while women may have an alternative protective mechanism involving estrogens.
Two genes, Lmx1a and Msx1, play a critical role in forming cerebral dopamine cells. This discovery can be used to control the formation of dopamine-producing cells from stem cells in a highly effective manner, representing an important step towards a stem-cell-based treatment for Parkinson's Disease.
A study led by scientists at Einstein and Beth Israel found a significant link between the G2019S LRRK2 gene mutation and Parkinson's disease in Ashkenazi Jewish patients. The mutation was detected in 18.3% of patients, highlighting the importance of genetic counseling for early detection and diagnosis.
A study found nearly 78% of test subjects had neurofibrillary tangles in the substantia nigra, linked to increased gait impairment. The relationship was independent of dementia status and only affected gait.
Researchers at Northwestern University have developed a gene therapy that turns off the alpha-synuclein protein, a key player in Parkinson's disease. The therapy uses RNA interference to selectively disable the gene, leaving other genes unaffected, and has shown promising results in rat models.
A major gene therapy advance for treating Parkinson's disease has been funded by the Fox Foundation grant, with RheoGene Inc. developing a technology to manage gene expression. The therapy uses a patented small-molecule mediator to turn genes on or off, offering a potential solution to replacing lost dopamine in the brain.
Scientists have identified 570 genes associated with Parkinson's disease, which could lead to the development of new treatments. The study analyzed brains from 23 patients and found that limiting the activity of these genes may help control or even stop the progression of the disease.
Scientists have engineered human brain progenitor cells to produce a growth factor that has shown clinical promise for treating Parkinson's disease. The cells were transplanted into rats and monkeys, delivering the drug where it is needed, promoting nerve fiber growth and improving survival of defective cells.
Researchers evaluated the effect of unilateral implantation of human RPE cells attached to gelatin microcarriers in six patients with advanced Parkinson disease. The study showed a 48% average improvement in motor symptoms at 12 months, sustained through 24 months, with no off-state dyskinesias observed.
A new guidance system automates electrode placement in DBS surgery, reducing operating times by up to 80% and improving patient outcomes. The system uses a 3D brain atlas to predict target locations, allowing neurosurgeons to hit the mark on their first try.
Researchers found highest increase in Parkinson's risk among highly educated individuals (9+ years of education), while physicians had the greatest increased risk compared to the general population. The study suggests that physical activity may protect against Parkinson's disease, but further studies are needed to confirm these findings.
David Eidelberg receives the prestigious Fred Springer Award for his work on mapping brain pathways and developing new diagnostic techniques. The award recognizes his pioneering efforts in viewing the brain at work, early diagnosis, and predicting treatment responses.
Researchers at Johns Hopkins have discovered a protein called LRRK2 that could be the best new target in the fight against Parkinson's disease. The study found that LRRK2 is involved in controlling other proteins' activities and may play a role in the death of brain cells that produce dopamine.
Researchers at OHSU found that mice consuming fewer calories experienced a boost in essential neurochemical glutamate, which reversed a Parkinson's-induced drop. The study suggests dietary restriction may be beneficial in early-stage Parkinson's disease.
Researchers discovered that alpha-synuclein, a disease-causing protein, has a protective effect against nerve damage in Parkinson's disease. This finding was made by studying mutant mice that were bred to have different levels of alpha-synuclein and cysteine-string-protein-alpha, a co-chaperone.
A recent study published in the Journal of the American Geriatrics Society found that older men with Parkinson's disease have significantly lower bone density at the spine and hip, increasing their risk for bone fractures. The study also revealed a nearly three times greater risk of multiple future falls among those with PD.
A woman's fear of falling led to a psychological disorder affecting her ability to walk, but treatment helped improve her bearing and mobility. After discovering the condition was not physically related, she began walking again after six months of physical therapy and reduced medication.
Researchers at the University of Wisconsin-Madison have developed a new lithium battery technology that can make batteries smaller, last longer, and accept external charging without surgery. This breakthrough technology uses organosilicon compounds to improve battery lifespan, enabling implantable devices such as pacemakers and microst...
The Phase I trial demonstrated the treatment's safety and efficacy in advanced Parkinson's disease, with statistically significant improvements in motor function and activities of daily living. The gene therapy approach offers a simpler alternative to deep brain stimulation, avoiding devices and requiring local anesthesia.
OHSU neurologists offer reliable strategies for diagnosing and managing Parkinson's disease. The article highlights the importance of non-pharmacological therapies such as exercise, nutrition, and emotional health in addition to pharmacological care.
The research provides a comprehensive whole genome map of genetic variability in Parkinson's disease, highlighting 12 potential 'susceptibility' genes. The findings may lead to new insights into the causes of Parkinson's disease and inform future research efforts.
Researchers created an animal model of Parkinson's disease using fruit flies with deleted DJ-1 genes, finding increased sensitivity to oxidative damage from common agricultural agents. The study suggests that DJ-1 plays a critical role in protecting dopaminergic neurons from oxidative stress.
Researchers discover that amphetamines can alter movement independently of dopamine, opening up new directions in the search for anti-Parkinsonian drugs. The findings suggest that drugs with similar chemical attributes might offer useful alternatives to current therapies.
Researchers have found that amphetamine-related drugs, such as MDMA, can effectively alleviate symptoms of Parkinson's disease in a mouse model. By eliminating dopamine recycling and production, these drugs bypass the usual limitations of L-DOPA treatment, offering new hope for patients with the debilitating condition.